Shenzhen Beimei Pharma completed A round financing

On 26th January 2021,Shenzhen Beimei Pharma Co., Ltd.(hereinafter referred to as "Beimei Pharma") officially announced the completion of A round financing of tens of millions of RMB, invested by Sunhope Investment Group(hereinafter referred to as "Sunhope"). This round of financing will be mainly used for R&D, import introduction and team expansion of pipelines and improved new drugs.

Beimei Pharma is focused in the field of pediatric prescription drugs, and committed to addressing the clinical needs of pediatric patients. For this mission, Beimei Pharma is committed to R&D, introduction of high-quality pediatric prescription drugs, focusing on the innovation of new and improved drugs, building a platform for taste masking and taste correction technology, and focusing on safe, convenient and precise drug delivery. With the vision of "providing high quality, full range of products for Chinese children", the company makes its own contribution to the health of Chinese children.

Wu Guangmei, CEO of Beimei Pharma, said: "We are very grateful to Sunhope Investment Group, for its optimism in Beimei Pharma’s positioning and accumulation in the field of of pediatric drugs, and for its high recognition of Beimei Pharma's values and give Beimei Pharma capital assistance. This round of financing is a recognition of our past performance in the field of pediatric drugs by Sunhope , as well as a recognition of our team and confidence in the future development of our company. The funds and quality resources obtained from this round of financing will be used to accelerate the advancement and expansion of our pipeline and introduction projects, helping Beimei Pharma to become the best pediatric drug company in China and to provide high quality safe and effective therapeutic drugs to Chinese children as soon as possible."

Ouyang Yiping, CEO of Sunhope Investment Group and Sunhope Investment Development Co., Ltd, said: "Beimei Pharma has a very clear and precise positioning and strategic development direction in the field of pediatric drugs, and its values are highly compatible with the philosophy of Sunhope Investment. Beimei Pharma has a professional and efficient team to bring high quality pediatric drugs from home and abroad to the Chinese market. We believe that Beimei Pharma will become a well-known and outstanding company in the field of pediatric drugs. We are honoured to have the opportunity to support such an outstanding team to help Beimei Pharma introducing leading international pediatric products into China, accelerate its own R&D and serve the vast number of pediatric patients in China faster."

About Sunhope Investment Group

Founded in 1994, Sunhope Investment Group is based in Shenzhen and has a global perspective, with investment management and asset operation as its two wings for steady development. The Group owns over 200,000 square feet of its own properties in the core area of Shenzhen CBD, with the strategic goal of "building a century-old company", specializing in winning, and moving steadily forward.

Focusing on the high-tech and health sectors, Sunhope Investment has invested in more than 40 projects in China, North America, Europe, Australia and Southeast Asia. At the same time, Xinhao Investment is deeply involved in industry-leading funds and projects such as Qianhai Mother Fund, Qianhai Equity Exchange Center, Shenzhen Venture Capital and Guangfeng Technology, completing vertical layout and horizontal linkage. Adhering to the basic philosophy of "global vision, value investment", Sunhope Investment runs alongside outstanding entrepreneurs, creating value for society and practicing "Sunhope the Good".

About Beimei Pharma

Beimei Pharma is focused in the field of pediatric prescription drugs, and aims to become a new-styled pharmaceutical company integrated with R&D, in-licensing, production and sales. It takes independent R&D and the in-licensing of domestic and international pediatric products as its strategic direction. The current product pipeline covers the respiratory, anti-infection (antibacterial), neuroscience, gastroenterology and others. Beimei Pharma is committed to providing Chinese pediatric patients with convenient, accurate, excellent-taste and high-quality products.